Tags

Type your tag names separated by a space and hit enter

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
J Clin Endocrinol Metab. 2019 05 01; 104(5):1595-1622.JC

Abstract

OBJECTIVE

The objective is to formulate clinical practice guidelines for the pharmacological management of osteoporosis in postmenopausal women.

CONCLUSIONS

Evidence from clinical trials and insights from clinical experience with pharmacologic therapies for osteoporosis were critically evaluated in formulating this guideline for the management of postmenopausal osteoporosis. Patient preferences, data on adherence and persistence, and risks and benefits from the patient and provider perspectives were also considered in writing committee deliberations. A consensus by the Writing Committee members was achieved for four management principles: (i) The risk of future fractures in postmenopausal women should be determined using country-specific assessment tools to guide decision-making. (ii) Patient preferences should be incorporated into treatment planning. (iii) Nutritional and lifestyle interventions and fall prevention should accompany all pharmacologic regimens to reduce fracture risk. (iv) Multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk with acceptable risk-benefit and safety profiles.

Authors+Show Affiliations

University of Sheffield, Sheffield, United Kingdom.Maine Medical Center Research Institute, Scarborough, Maine.University of California San Francisco, San Francisco, California.University of Toronto, Toronto, Ontario, Canada.Mayo Clinic Evidence-Based Practice Center, Rochester, Minnesota.Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, San Francisco, California. Department of Medicine, University of California San Francisco, San Francisco, California.

Pub Type(s)

Journal Article
Practice Guideline
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30907953

Citation

Eastell, Richard, et al. "Pharmacological Management of Osteoporosis in Postmenopausal Women: an Endocrine Society* Clinical Practice Guideline." The Journal of Clinical Endocrinology and Metabolism, vol. 104, no. 5, 2019, pp. 1595-1622.
Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622.
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019). Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 104(5), 1595-1622. https://doi.org/10.1210/jc.2019-00221
Eastell R, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 05 1;104(5):1595-1622. PubMed PMID: 30907953.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. AU - Eastell,Richard, AU - Rosen,Clifford J, AU - Black,Dennis M, AU - Cheung,Angela M, AU - Murad,M Hassan, AU - Shoback,Dolores, PY - 2019/01/28/received PY - 2019/01/28/accepted PY - 2019/3/26/pubmed PY - 2020/2/25/medline PY - 2019/3/26/entrez SP - 1595 EP - 1622 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 104 IS - 5 N2 - OBJECTIVE: The objective is to formulate clinical practice guidelines for the pharmacological management of osteoporosis in postmenopausal women. CONCLUSIONS: Evidence from clinical trials and insights from clinical experience with pharmacologic therapies for osteoporosis were critically evaluated in formulating this guideline for the management of postmenopausal osteoporosis. Patient preferences, data on adherence and persistence, and risks and benefits from the patient and provider perspectives were also considered in writing committee deliberations. A consensus by the Writing Committee members was achieved for four management principles: (i) The risk of future fractures in postmenopausal women should be determined using country-specific assessment tools to guide decision-making. (ii) Patient preferences should be incorporated into treatment planning. (iii) Nutritional and lifestyle interventions and fall prevention should accompany all pharmacologic regimens to reduce fracture risk. (iv) Multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk with acceptable risk-benefit and safety profiles. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/30907953/Pharmacological_Management_of_Osteoporosis_in_Postmenopausal_Women:_An_Endocrine_Society__Clinical_Practice_Guideline_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2019-00221 DB - PRIME DP - Unbound Medicine ER -